AUTHORS
Adam D. Cohen, MD, Sandra Susanibar-Adaniya, MD, MS2, Heta Patel, MD3, Fatma Betul Yilmaz, MD4, Alfred L. Garfall, MD5, Dan T. Vogl, MD, MSCE6, Shivani Kapur, MD7, Adam Waxman, MD, MS8, Danielle Zubka, RN9, Wei-Ting Hwang, PhD10, Cynthia Diaczynsky11, Elina Thai12, Alan Zheng13, Alexandria Raday14, Katie Alexander15, Matthew Ho, MBBS, PhD16, Luca Paruzzo, MD17, Marco Ruella, MD18, Joseph Fraietta, PhD19, Edward A. Stadtmauer, MD20
AFFILIATIONS
1 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
2 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
3 University of Pennsylvania, Philadelphia, Pennsylvania, United States
4 University of Pennsylvania, Philadelphia, Pennsylvania, United States
5 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
6 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
7 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
8 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
9 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
10 University of Pennsylvania, Philadelphia, Pennsylvania, United States
11 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
12 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
13 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
14 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
15 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
16 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
17 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
18 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
19 Center for Cellular Immunotherapies, University of Pennsylvania, Philadelphia, Pennsylvania, United States
20 Abramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania, United States
ABSTRACT
Background: BCMA-targeted CAR T cells have unprecedented activity in relapsed/refractory multiple myeloma (RRMM), but most patients (pts) relapse. Resistance mechanisms include poor CAR T cell persistence or function and BCMA-low or -negative residual tumor cells. FcRH5 is a MM antigen expressed independently of BCMA. Cevostamab (cevo) is an FcRH5-targeted T cell-engaging bispecific antibody with single-agent activity in RRMM, including after BCMA-directed therapy. We hypothesized that fixed-duration cevo following BCMA-targeted CAR T cells would be feasible, tolerable and improve sustained minimal residual disease (MRD)-negative complete response (CR) rates.
Methods: In this single-institution, investigator-initiated study (NCT05801939), RRMM pts with stable disease or better after standard-of-care CAR T cells (ide-cel or cilta-cel) received cevo beginning 10-12 weeks after CAR T cell infusion. After a 6-pt safety run-in, we proceeded with a step-up dose of 3.6 mg IV on Cycle 1 Day 1 (C1D1), followed by 132mg on C1D8 and every 3 weeks thereafter for 8 cycles. If pts had MRD-negative CR after 8 cycles (Adaptive Clonoseq, at 10-5 sensitivity), they stopped therapy and were observed. If not, they received another 8 cycles. The primary endpoint was rate of MRD-negative CR at 12 months post-CAR T cell therapy. All pts received IVIG prophylaxis.
Results: Twenty-seven pts (20M, 7F; median age 64 (range 33-80); 21 White, 6 Black) were enrolled from 7/2023 – 6/2025. Twenty (74%) had high risk cytogenetics (t(4;14), t(14;16), -17p, -1p, or +1q), with 11 (41%) having ≥2 abnormalities; 5 (19%) had extramedullary disease. Median number of prior lines was 4 (range 2-10), with 74% triple-class refractory, 11% prior BCMA therapy, and 11% prior talquetamab. Twenty-five (93%) received cilta-cel and 2 (7%) ide-cel. Reponses at enrollment (post-CAR T cells) were 63% CR/sCR, 15% VGPR, 18% PR, 4% SD; 25 were evaluable for MRD, with 100% MRD-negative at 10-5. As of 6/26/26 data cut-off, all pts have completed therapy, and no dose-limiting toxicities (DLTs) were seen. CRS occurred in 4 pts (15%, 3 G1, 1 G2) and infusion reactions in 22% (all G1/2); no ICANS, HLH, or delayed neurotoxicity were seen. Median number of cycles was 8; 7 (26%) pts held 1 or more doses of cevo due to toxicity and 6 (22%) had dose reductions to 90mg. Only 3 pts required the 2nd 8 cycles of cevo. Common treatment-emergent adverse events (TEAE’s), regardless of attribution, were neutropenia (78%, G3/4 48%), lymphopenia (74%, G3/4 67%), cough (63%, G3/4 0%), rash (48%, G3/4 0%), upper respiratory infection (44%, G3/4 0%), thrombocytopenia (41%, G3/4 22%), nasal congestion (37%, G3/4 0%), and AST increase (33%, G3/4 7%). Infections occurred in 70% (G3/4 in 15%), and serious AE’s in 44%. As previously reported, immune-related AE’s occurred in 4 pts (colitis G2, neuropathy with ataxia G3, ITP G4 (n=2), autoimmune hepatitis G1) – all resolved.
At 1 year post-CAR T cells, 89% of pts (24/27) had sCR and 7% (2/27) VGPR. By Clonoseq 25/26 (96%) were MRD-negative at 10-5, and 23/26 (88%) at 10-6. One sCR pt unevaluable by Clonoseq was MRD-negative by flow cytometry (10-5 sensitivity). The 1-year MRD-negative (at 10-5 sensitivity) CR rate (primary endpoint) was 89% (24/27 pts). With median follow-up of 24 months (range 15-37) post-CAR T cells, 2 patients have progressed (at 5 and 15 months post-CAR T cells), and estimated 24-month PFS and OS are 93% and 96%, respectively. Based on peripheral blood CAR transgene qPCR (n=25, all cilta-cel), 10 pts (40%) had transient CAR transgene increase (≥20% increase over prior transgene level) after starting cevo, usually during C1, though 4 pts had a later second increase. At 12 months post-CART infusion, 11 pts (44%) still had detectable transgene levels > 10 copies/μg.
Conclusions: Fixed-duration cevostamab consolidation starting 10-12 weeks post-CAR T cells is feasible and well-tolerated in heavily-pretreated RRMM, with low rates of non-hematologic G3/4 TEAE’s, including infections, though reversible immune-related AE’s occurred. Efficacy appears promising, with 89% of pts having sustained MRD-negative CR at 1 year, and estimated 2-year PFS was 93%. Transient CAR T cell re-expansion was observed. Additional correlative analyses and follow-up are ongoing.
DISCLOSURES
Adam D. Cohen, MD: Janssen Oncology - Research Funding; Roche/Genentech - Research Funding; GSK - Research Funding; Novartis - Research Funding; Patents related to CAR T cells and biomarkers of Cytokine Release Syndrome - Patents & Royalties; Regeneron - Consultancy (Includes expert testimony); Kite - Consultancy (Includes expert testimony); ITeos Therapeutics - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Arcellx - Consultancy (Includes expert testimony); AbbVie - Consultancy (Includes expert testimony); Janssen Oncology - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Ichnos Sciences - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Legend - Consultancy (Includes expert testimony); Prothena - Consultancy (Includes expert testimony); Roche/Genentech - Consultancy (Includes expert testimony); Moderna - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony)